FDMT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 105706 min ago

@ $27.97

Wydano: 14 vas. 2024 @ 22:13

Zwrot: -16.88%

Poprzedni sygnał: vas. 14 - 20:43

Poprzedni sygnał: Kupno

Zwrot: 2.04 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	317 415
Średni wolumen	1.21M
Kapitalizacja rynkowa	1.19B
EPS	$0 ( 2024-03-20 )
Następna data zysków	( $-0.730 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.01
ATR14	$0.0280 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: 0.80 (moderate)

Signal:(50.646) Neutral

4D Molecular Korelacja

10 Najbardziej pozytywne korelacje
AFYA	0.848
RMCF	0.839
GOEV	0.826
NTCT	0.826
SLM	0.821
IMGN	0.818
TRMK	0.817
NDAQ	0.817
PRCT	0.816
LSXMA	0.816

10 Najbardziej negatywne korelacje
ISDX	-0.838
ZIONP	-0.827
TRHC	-0.826
NVSAU	-0.823
KSICU	-0.822
IOAC	-0.821
GRBK	-0.815
XFIN	-0.813
VRIG	-0.812
BRIVU	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

4D Molecular Korelacja - Waluta/Towar

0.09
( neutral )

0.05
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.08
( neutral )

0.07
( neutral )

4D Molecular Finanse

Annual	2023
Przychody:	$20.72M
Zysk brutto:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
Przychody:	$20.72M
Zysk brutto:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
Przychody:	$3.13M
Zysk brutto:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
Przychody:	$18.04M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.